5 FDA Decisions for Primary Care to Know from April 2026

In April, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning obesity management, infectious disease, rare genetic conditions, and diabetes care. The following list highlights 5 key updates for primary care, including approval of a novel oral GLP-1 receptor agonist for weight management, a new 2-drug regimen for virologically suppressed HIV, a first-in-class gene therapy for inherited hearing loss, and expanded use of automated insulin delivery technology in pregnancy.

Several of the actions reflect continued innovation in therapeutic design, including the expansion of oral treatment options and the advancement of gene-based therapies targeting underlying disease mechanisms. These developments point to a broader shift toward more individualized and potentially less burdensome treatment strategies across a range of chronic and rare conditions.

Additional updates focus on diabetes care and chronic disease management, where both pharmacologic and technology-driven approaches continue to evolve. Together, these decisions underscore ongoing regulatory momentum in areas highly relevant to primary care and signal emerging options that may influence future treatment pathways.

1. FDA Approves Lumateperone sNDA for Schizophrenia Relapse Prevention

On April 27, 2026, Johnson & Johnson announced US FDA approval of a supplemental New Drug Application (sNDA) for lumateperone (Caplyta^®) to include relapse prevention data in adults with schizophrenia. Based on the phase 3 Study 304 randomized withdrawal trial, lumateperone significantly prolonged time to relapse vs placebo (P = .0002), with a 63% lower relative risk of relapse (HR 0.37) and 84% of patients remaining relapse-free over 6 months. The safety profile was consistent with prior data, with no new safety signals identified and no clinically meaningful metabolic changes observed. The label update adds long-term relapse prevention evidence to existing indications for schizophrenia and mood disorders.

2. FDA Clears Control-IQ+ for Pregnancy in Type 1 Diabetes

On April 27, 2026, Tandem Diabetes Care announced US FDA clearance of Control-IQ+ automated insulin delivery technology for use during pregnancy in individuals with type 1 diabetes. Based on results from the CIRCUIT randomized controlled trial, use of Control-IQ increased time in the pregnancy-specific glucose range (63–140 mg/dL) by 12.6%, or approximately 3 additional hours per day, compared with standard insulin therapy. The system is now the first FDA-cleared automated insulin delivery technology indicated for pregnancy in the US, expanding use of hybrid closed-loop insulin delivery to this high-risk population. The technology integrates continuous glucose monitoring data to automatically adjust basal insulin and deliver correction doses in real time.

3. FDA Approves Doravirine/Islatravir Once-Daily 2-Drug Regimen for Virologically Suppressed HIV-1

On April 21, 2026, Merck announced US FDA approval of a fixed-dose combination of doravirine 100 mg/islatravir 0.25 mg for the treatment of virologically suppressed adults with HIV-1 infection as a switch regimen. Based on phase 3 noninferiority trials (NCT05630755; NCT05631093; n=708), the regimen maintained viral suppression in 92%–96% of patients at week 48, with noninferior efficacy vs standard 3-drug regimens. The once-daily, single-tablet therapy is the first non-INSTI, tenofovir-free, complete 2-drug regimen to demonstrate such outcomes. The safety profile was generally comparable to existing regimens, with low discontinuation rates and similar adverse event profiles.

4. FDA Grants Accelerated Approval to First Gene Therapy for Genetic Hearing Loss

On April 23, 2026, Regeneron Pharmaceuticals announced US FDA accelerated approval of lunsotogene parvec-cwha (Otarmeni^®) for the treatment of genetic hearing loss caused by biallelic OTOF variants. Based on results from the phase 1/2 CHORD trial (n=20), 80% of participants achieved hearing thresholds ≤70 dB HL at 24 weeks, with 70% meeting key auditory response endpoints and some attaining normal hearing levels. The one-time intracochlear gene therapy demonstrated rapid and sustained improvements in hearing through 48 weeks, though long-term durability remains under study. This approval represents the first gene therapy indicated to restore neurosensory hearing function in this rare genetic condition.

5. FDA Approves Orforglipron, First Oral GLP-1 Receptor Agonist for Weight Loss With No Food or Water Restrictions

On April 1, 2026, Eli Lilly and Company announced US FDA approval of orforglipron (Foundayo^®) for the treatment of chronic weight management in adults with obesity or overweight with at least 1 weight-related comorbidity. Based on the phase 3 ATTAIN clinical trial program (n > 4500), the highest dose achieved mean weight loss of 11.2% at 72 weeks, with 54.6% of participants achieving ≥10% weight loss vs 12.9% with placebo (P < .001). The therapy is a nonpeptide, small-molecule oral GLP-1 receptor agonist that can be taken without fasting or food restrictions, distinguishing it from existing oral GLP-1 options. The safety profile was consistent with the GLP-1 class, with gastrointestinal adverse events most commonly reported.